Drugs / MBA-P01
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03547141 | Apr → Aug 2018 | — | Medy-Tox | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05217355 | Dec 2021 → Jun 2022 | — | Medytox Korea | Completed | No outcome recorded |
| Phase 2 | NCT04143854 | May 2019 → Aug 2020 | eyelid disorder | Medy-Tox | Completed | No outcome recorded |
| Phase 2 | NCT04143815 | May 2019 → Sep 2020 | — | Medy-Tox | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05321979 | Feb 2022 → May 2023 | — | Medytox Korea | Completed | No outcome recorded |
| Phase 3 | NCT05059587 | Aug → Dec 2021 | — | Medytox Korea | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MBA-P01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05217355 ↗ |
| Known as | Botulinum toxin A | “MBA-P01 (Botulinum toxin A)” NCT05217355 ↗ |
| Modality | Protein / enzyme biologic | “MBA-P01 (Botulinum toxin A)” NCT05217355 ↗ |
| Route | Intramuscular | “injection of MBA-P01 into the muscle of each contralateral foot in equal doses” NCT03547141 ↗ |